查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1545387

速效型胰島素的全球市場的預測:各產品，各適應症，各流通管道，各國，企業的分析

Global Rapid Acting Insulin Market Report Forecast by Product Indication Distribution Channel, Countries and Company Analysis
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

速效胰島素市場分析

全球速效胰島素市場規模預計將從 2023 年的 73.6 億美元增至 2032 年的 111.7 億美元，複合年增長率為 4.75%。該市場主要受到糖尿病成長率和人類重組胰島素研發投資增加的推動。

推動速效胰島素市場成長的因素

全球糖尿病盛行率不斷上升

全球糖尿病盛行率的上升也是推動速效胰島素市場快速成長的因素之一。根據國際糖尿病聯盟的數據，截至 2019 年，有 4.63 億成年人患有糖尿病，到 2045 年，這一數字可能達到 7 億。這種增長是由於不良飲食習慣、缺乏運動、超重和肥胖以及嬰兒潮世代的老化所造成的。全球第2型糖尿病的盛行率正在增加，隨著患者數量的增加，對包括胰島素在內的高效能血糖控制產品的需求也增加。此外，診斷技術的改進有助於識別病例，新興國家對糖尿病治療認識的提高導致糖尿病早期檢測和早期治療的進步，速效胰島素產品的市場正在全球擴大。

胰島素輸送系統技術的進展

增強胰島素輸送系統是全球速效胰島素需求的主要成長因素。隨著速效胰島素的廣泛使用，胰島素筆、幫浦和智慧胰島素輸送系統的發展提高了基礎推注和速效胰島素給藥的簡單性和精確度。 CGM 和胰島素幫浦的組合可以實現準確的劑量和更好的血糖控制，因為 CGM 系統提供比傳統血糖自我監測更多的資訊。閉環系統，或所謂的“人工胰臟”，可以根據即時血糖水平調整胰島素劑量，在速效胰島素方面擁有堅實的基礎。這些發展將帶來更好的患者治療結果，改善患者的生活質量，並增加使用速效胰島素製劑的趨勢，從而促使市場成長。

日益關注個人化糖尿病管理

糖尿病疾病管理中的個人化醫療將增加對速效胰島素的需求。如今，2 型糖尿病患者在製定個人化治療方案時會考慮患者的生活方式、飲食偏好、遺傳因素等。第二種胰島素的優點是劑量和時間更靈活。新型胰島素（超速效）也很重要，因為它們提供了更個人化的治療選擇。個人化的糖尿病治療方法還可以促進胰島素敏感性遺傳決定因素的研究，並有助於制定個人化治療策略。個人化趨勢的不斷增長也促進了RAPI產品的多樣化，尤其是速效胰島素，預計將推動市場的進一步成長。

中國速效胰島素市場

由於糖尿病患者數量的增加以及人們糖尿病管理知識的提高，中國的速效胰島素市場正在不斷擴大。 2021年，全球將有1.41億成年人患有糖尿病，而中國這個全球人口最多的國家也無法倖免這項負擔。

速效胰島素對於控制餐前血糖特別有用。這些胰島素在註射後 15 分鐘內開始發揮作用，有助於防止餐後血糖升高。中國當局正努力普及糖尿病治療和胰島素，以促進市場擴張。然而，挑戰仍然存在，包括病患教育、在農村地區發展更好的醫療保健系統以及成本問題。隨著中國繼續致力於醫療改革和慢性病管理，速效胰島素市場預計將成長，為現有企業和新進業者創造機會。 2024年5月，禮來公司的抗糖尿病藥物三勝?獲得上市許可，進入中國市場，加劇了與丹麥同行諾和諾德在西方的競爭。

本報告提供全球速效型胰島素市場相關調查，提供成長推動因素與課題，地區和市場區隔的分析，主要企業的分析等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 成長促進因素
  • 課題
  • 機會

第5章 全球速效型胰島素市場

第6章 市場佔有率分析

  • 各產品
  • 各適應症
  • 各流通管道
  • 各國

第7章 產品

  • Lispro胰島素
  • Aspart胰島素
  • Glulisine胰島素

第8章 適應症

  • 第一型糖尿病
  • 第二型糖尿病

第9章 流通管道

  • 醫院藥局
  • 藥妝店，零售藥局
  • 網路商店

第10章 國家

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 比利時
    • 荷蘭
    • 土耳其
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
    • 馬來西亞
    • 印尼
    • 紐西蘭
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東·非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第11章 波特的五力分析

第12章 SWOT分析

第13章 主要企業的分析

  • Adocia
  • Biocon Limited
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals Co. Ltd.
  • Geropharm
  • MannKind Corporation
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Wockhardt Ltd.
簡介目錄

Rapid Acting Insulin Market Analysis

The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11. 17 billion by 2032, from US$ 7. 36 billion in 2023. The market is mainly driven by growth rate of diabetes and the rise in investment in research and development for human recombinant insulin.

Rapid Acting Insulin Industry Overview

A rapid-acting insulin is intended to imitate the body's reaction to the consumption of various foods as industrial insulin imitates natural insulin. It causes effective response 15 minutes after injection and reaches its maximum effect after about 1 hour and lasts 2 to 4 hours. This type of insulin is generally employed for administration before meals, and for the treatment of hyperglycemia. It is taken 15 minutes before eating a meal or within 30 minutes after eating a meal; this flexibility is different from human insulin. The standard rapid-acting analogue insulins are insulin lispro insulin as part and insulin glulisine. On the basis of structure, these insulins have a more rapid onset and a relatively shorter duration of action than the regular insulin.

Globally, rapid acting insulin has turned into an essential part of controlling both type 1 and type 2 diabetes. It is employed in multiple daily injections and insulin pump therapy in the developed regions as it provides better glycemic control and increased modem freedom to the patients. The fast-acting insulin availability over the past years has increased, and people from many developing countries can get them, but issues with availability and cost remain relevant in some territories. With the rising incidence of diabetes and the improved understanding and acceptance of the benefits of achieving better control of blood glucose levels and, therefore, a reduction in the incidence of microvascular complications of diabetes by using rapid-acting insulin, its use across the world is likely to increase further. Having understood the importance of insulin, research is still being conducted to determine even faster acting insulins, and better ways of administering the insulin in the management of diabetes.

Growth Drivers of the Rapid-Acting Insulin Market

Rising global diabetes prevalence:

The global occurrence of diabetes has also risen at a high rate and this is one which has made the market for rapid acting insulin to grow rapidly as well. The International Diabetes Federation indicates that as per 2019, 463 million adults suffer from diabetes, and this figure could reach 700 million by 2045. This rise is as a result of poor dieting, physical inactivity, overweight and obesity, as well as aging baby boomers. The global type 2 diabetes prevalence is increasing, and with the increase in the number of cases, there is the demand for efficient blood glucose control products, including insulin. In addition, more identification of cases through technological enhancement in diagnosing the disease and growth awareness of diabetes care in the emerging nation progress early detection and treatment of diabetes more market for rapid-acting insulin product in the world.

Technological advancements in insulin delivery systems:

Enhancements of insulin delivery systems are prospectively the major growth contributors to the global demand of rapid-acting insulin. Growth of insulin pens, pumps, and smart insulin-delivery systems has increased the usability and accuracy of basal bolus and rapid-acting insulin administration with broader use of rapid-acting insulin. CGM and insulin pump combination makes the accurate dosing and good glycemic control because CGM systems provide more information than traditional self-monitoring of blood glucose. Closed loop systems or what is also known as 'the artificial pancreas' that regulates insulin dosage with reference to real time glucose levels has a strong foundation by virtue of rapid-acting insulins. Such developments bring the better outcomes for the patients and increase patients' quality of life, their tendency to use the rapid-acting insulins and, therefore, the market growth.

Increasing focus on personalized diabetes management:

Personalized medicine in the management of diabetic diseases increases the growth in the demand for rapid-acting insulin. Today, the patients with diabetes type 2 are developing personalized programs of the disease treatment which taken into consideration the patient's lifestyle, preferences in terms of diet, and hereditary factors. The second type of insulin has the advantage of more flexibility in dosing and in timing. Also important is that new types of insulin - ultra-rapid-acting - mean even more choice for personalized treatment. Also, the personalized approach to diabetes management fuels investigations into genetic determinants of insulin sensitivity which might contribute to development of individualized treatment strategies. The increasing trend of individualization also contributes to several RAPI products, particularly various products of rapid-acting insulin, which will unlock the market's growth further.

China Rapid Acting Insulin Market

China's market for rapid-acting insulin is expanding because of the rising instances of diabetes and people's enhanced knowledge of how to manage the condition. In 2021, 141 million adults live with the disease globally and China being the most populous country in the world is not exempted from this burden.

Fast-acting insulin or rapid-acting insulin is helpful in controlling blood sugar especially before meals. These insulins begin to act within fifteen minutes of injection and act to prevent the post-prandial rise in blood glucose. The Chinese authorities have undertaken efforts to enhance the treatment of diabetes and the availability of Insulin, thus contributing to market progression. Nevertheless, difficulties persist, such as patient enlightenment, development of a better rural health system, as well as the question of cost. Since China will maintain its efforts in the healthcare reform and the management of chronic disease, the market for rapid-acting insulin is expected to grow and can create opportunities for the existing players as well as the newcomers. In May 2024, Eli Lilly entered the Chinese market securing approval to sell its diabetes drug tripeptide, ramping up a Europe and North America fight with Danish peer Novo Nordisk.

Rapid Acting Insulin Company Analysis

The Rapid Acting Insulin market is dominated by several leading companies, including Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., and Wockhardt Ltd. These companies are at the forefront of developing and manufacturing rapid-acting insulin products, playing a vital role in meeting the world healthcare needs of individuals with diabetes.

Rapid Acting Insulin Company News

In March 2023, Sanofi in India received marketing authorization from the Central Drugs Standard Control Organization for its diabetes medication Soliqua, available in a pre-filled pen.

In November 2023, USV Pvt Ltd and Biogenomics launched INSUQUICK, India's first biosimilar Insulin part, to improve access for people with diabetes.

April 2023, Insulet Corporation's latest innovation, Omnipod GO, has received FDA clearance as an insulin delivery device for people with type 2 diabetes, specifically for those aged 18 or older who usually require daily injections of long-acting insulin.

Product - Market breakup in 3 viewpoints:

1. Lispro Insulin

2. Aspart Insulin

3. Glulisine Insulin

Indication - Market breakup in 2 viewpoints:

1. Type 1 Diabetes

2. Type 2 Diabetes

Distribution Channel - Market breakup in 3 viewpoints:

1. Hospital Pharmacies

2. Drug Stores and Retail Pharmacies

3. Online Stores

Countries - Market breakup in 25 viewpoints:

  • North America

United States

Canada

  • Europe

France

Germany

Italy

Spain

United Kingdom

Belgium

Netherland

Turkey

  • Asia Pacific

China

Japan

India

South Korea

Thailand

Malaysia

Indonesia

Australia

New Zealand

  • Latin America

Brazil

Mexico

Argentina

  • Middle East & Africa

Saudi Arabia

UAE

South Africa

All the key players have been covered from 5 Viewpoints:

  • Overview
  • Key Persons
  • Product Portfolio
  • Recent Development
  • Revenue Analysis

Key Players Analysis:

1. Adocia

2. Biocon Limited

3. Eli Lilly and Company

4. Gan & Lee Pharmaceuticals Co. Ltd.

5. Geropharm

6. MannKind Corporation

7. Merck & Co. Inc.

8. Novo Nordisk A/S

9. Sanofi S.A.

10. Wockhardt Ltd.

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges
  • 4.3 Opportunities

5. Global Rapid Acting Insulin Market

6. Market Share Analysis

  • 6.1 By Product
  • 6.2 By Indication
  • 6.3 By Distribution Channel
  • 6.4 By Countries

7. Product

  • 7.1 Lispro Insulin
  • 7.2 Aspart Insulin
  • 7.3 Glulisine Insulin

8. Indication

  • 8.1 Type 1 Diabetes
  • 8.2 Type 2 Diabetes

9. Distribution Channel

  • 9.1 Hospital Pharmacies
  • 9.2 Drug Stores and Retail Pharmacies
  • 9.3 Online Stores

10. Countries

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherland
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 Australia
    • 10.3.5 South Korea
    • 10.3.6 Thailand
    • 10.3.7 Malaysia
    • 10.3.8 Indonesia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 South Africa
    • 10.5.2 Saudi Arabia
    • 10.5.3 UAE

11. Porter's Five Forces Analysis

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Rivalry
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threat

13. Key Players Analysis

  • 13.1 Adocia
    • 13.1.1 Overview
    • 13.1.2 Key Persons
    • 13.1.3 Product Portfolio
    • 13.1.4 Recent Development
    • 13.1.5 Revenue Analysis
  • 13.2 Biocon Limited
    • 13.2.1 Overview
    • 13.2.2 Key Persons
    • 13.2.3 Product Portfolio
    • 13.2.4 Recent Development
    • 13.2.5 Revenue Analysis
  • 13.3 Eli Lilly and Company
    • 13.3.1 Overview
    • 13.3.2 Key Persons
    • 13.3.3 Product Portfolio
    • 13.3.4 Recent Development
    • 13.3.5 Revenue Analysis
  • 13.4 Gan & Lee Pharmaceuticals Co. Ltd.
    • 13.4.1 Overview
    • 13.4.2 Key Persons
    • 13.4.3 Product Portfolio
    • 13.4.4 Recent Development
    • 13.4.5 Revenue Analysis
  • 13.5 Geropharm
    • 13.5.1 Overview
    • 13.5.2 Key Persons
    • 13.5.3 Product Portfolio
    • 13.5.4 Recent Development
    • 13.5.5 Revenue Analysis
  • 13.6 MannKind Corporation
    • 13.6.1 Overview
    • 13.6.2 Key Persons
    • 13.6.3 Product Portfolio
    • 13.6.4 Recent Development
    • 13.6.5 Revenue Analysis
  • 13.7 Merck & Co. Inc.
    • 13.7.1 Overview
    • 13.7.2 Key Persons
    • 13.7.3 Product Portfolio
    • 13.7.4 Recent Development
    • 13.7.5 Revenue Analysis
  • 13.8 Novo Nordisk A/S
    • 13.8.1 Overview
    • 13.8.2 Key Persons
    • 13.8.3 Product Portfolio
    • 13.8.4 Recent Development
    • 13.8.5 Revenue Analysis
  • 13.9 Sanofi S.A.
    • 13.9.1 Overview
    • 13.9.2 Key Persons
    • 13.9.3 Product Portfolio
    • 13.9.4 Recent Development
    • 13.9.5 Revenue Analysis
  • 13.10 Wockhardt Ltd.
    • 13.10.1 Overview
    • 13.10.2 Key Persons
    • 13.10.3 Product Portfolio
    • 13.10.4 Recent Development
    • 13.10.5 Revenue Analysis